Structure-based screening of low-affinity compounds

Drug Discovery Today

Volumn 7, Issue 9, 2002, Pages 522-527

  Carr, Robin ^a   Jhoti, Harren ^a  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; PROTEIN;

BINDING AFFINITY; BIOASSAY; DEVICE; INTERMETHOD COMPARISON; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE; PROTEIN STRUCTURE; REVIEW; SCREENING TEST; X RAY CRYSTALLOGRAPHY; DRUG DESIGN;

CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN;

EID: 0036558207     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02245-6     Document Type: Review

References (36)

1. Accelerating R&D productivity
2. Science, art and drug discovery: A personal perspective
3. Is there a difference between leads and drugs? A Historical Perspective
4. Molecular complexity and its impact on the probability of finding leads for drug discovery
5. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
6. High-throughput X-ray crystallography for drug discovery
7. Discovering high-affinity ligands for proteins: SAR by NMR
8. NMR-based screening in drug discovery
9. The SHAPES strategy: An NMR-based approach for lead generation in drug discovery
10. Discovering novel ligands for macromolecules using X-ray crystallographic screening
11. Novel inhibitors of DNA gyrase: 3D structure-based biased needle screening, hit validation by biophysical methods and 3D guided optimization. A promising alternative to random screening
12. Automation of X-ray crystallography
13. High-throughput structural proteomics using X-rays
14. High-throughput three-dimensional protein structure determination
15. High-throughput crystallography for lead discovery in drug design
16. High-throughput proteomics: Protein expression and purification in the post-genomic world
17. High-throughput protein crystallization
18. Recent developments in software for the automation of crystallographic macromolecular structure determination
19. Structural genomics programs at the US National Institute of General Medical Sciences
20. Structural genomics in the biotechnology sector
21. Global efforts in structural genomics
22. The Protein Data Bank and the challenge of structural genomics
23. Drug discovery: A historical perspective
24. Synchrotron crystallography
25. Experiences with CCD detectors on a home X-ray source
26. Automated crystal mounting and data collection for protein crystallography
27. Antitrypanosomiasis drug development based on structures of glycolytic enzymes
28. Virtual screening - An overview
29. Development and validation of a genetic algorithm for flexible docking
30. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes
31. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations
32. The properties of known drugs. 1. Molecular frameworks
33. Properties of known drugs. 2. Side chains
34. 1-Aminoisoquinoline as benzamidine isoster in the design and synthesis of orally active thrombin inhibitors
35. Design of adenosine kinase inhibitors from the NMR-based screening of fragments